Breaking News Instant updates and real-time market news.

ONCE

Spark Therapeutics

$54.07

1.21 (2.29%)

15:57
01/12/18
01/12
15:57
01/12/18
15:57

Spark Therapeutics' Luxturna does not meet ICER cost-effectiveness standards

The Institute for Clinical and Economic Review, or ICER, released its revised evidence report assessing the comparative clinical effectiveness and value of Luxturna, Spark Therapeutics for treatment of vision loss associated with biallelic RPE65-mediated retinal disease. This evidence report will be the subject of an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council, or CEPAC, on January 25. The Midwest CEPAC is one of ICER's three independent evidence appraisal committees. Evidence on Luxturna provides high certainty of at least a small net health benefit for patients with biallelic RPE65-mediated retinal disease; however, significant uncertainty remains about the long-term effects and durability of the response to treatment. Assuming a 10-20 year benefit of treatment for 15-year-olds, the average age of patients in the clinical trials, economic analyses found that at the current price of $850,000, use of the treatment would exceed common cost-effectiveness thresholds.

  • 12

    Jan

  • 26

    Feb

ONCE Spark Therapeutics
$54.07

1.21 (2.29%)

12/19/17
CANT
12/19/17
NO CHANGE
Target $105
CANT
Overweight
Spark approved label 'extremely attractive,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros believes the FDA approved label for Spark Therapeutics' Luxturna is "extremely attractive" as anyone with confirmed mutations above the age of one can be treated with the gene therapy. The analyst estimates there are 3,500 eligible patients in the U.S. and key European countries. He expects the treatment cost to be approximately $1M per year per patient. As such, every 500 patients could represent $500M revenue to Spark, Piros tells investors in a research note. The analyst keeps an Overweight rating on the shares with a $105 price target. Spark Therapeutics in afternoon trading is down 3.5% to $47.32.
01/03/18
STFL
01/03/18
NO CHANGE
Target $73
STFL
Buy
Spark's 'innovative' Luxturna access proposals a positive, says Stifel
Stifel analyst Stephen Willey said Spark Therapeutics' "innovative" reimbursement proposals for Luxturna are an incremental positive, adding that he sees the CMS proposal of providing the option to spread payment over multiple years as the one most likely to help longer-term investor perception. Willey adds that the $850,000 wholesale acquisition cost is exactly in-line with his estimate, but below the $500,000 per eye that had been positioned by the company and assumed by the consensus view. The analyst, who still thinks the current stock price gives zero value to "anything hemophilia-related," keeps a Buy rating and $73 price target on Spark shares.
01/03/18
JEFF
01/03/18
NO CHANGE
Target $72
JEFF
Buy
Spark Therapeutics drug pricing in-line with expectation, says Jefferies
Jefferies analyst Michael Yee says the $425,000 per eye price of Luxturna announced by Spark Therapeutics is relatively in-line with his expectation of $900,000 per patient. The number is "rightfully below the $1M per patient headline price that wouldn't be necessary," Yee tells investors in a research note. He finds it important that Spark also announced three related reimbursement programs that work to ensure payments are based on outcomes and payments can be spread out over time to reduce the upfront burdens. The analyst feels "generally comfortable" with his 2018 U.S. revenue estimate of $45M-$50M on 80-90 treated patients, although he notes the consensus is likely higher between $55M-$65M. Yee has a Buy rating on Spark Therapeutics with a $72 price target.
01/04/18
RHCO
01/04/18
NO CHANGE
Target $113
RHCO
Buy
Spark Therapeutics price target raised to $113 from $101 at SunTrust
SunTrust analyst Edward Nash raised his price target on Spark Therapeutics to $113 after the company's announcement of Luxturna price of $425K per dose. While the post-adjustment wholesale acquisition cost of $680K per patient is lower than the $1M forecast by the Street, the analyst says the company's proposed three payer programs will bolster Luxturna's uptake, adding he is "encouraged by the strides Spark has made in engaging with payers on Luxturna's pricing and reimbursement strategies". Nash keeps his Buy rating on Spark Therapeutics.

TODAY'S FREE FLY STORIES

QD

Qudian

$12.50

0.1 (0.81%)

12:45
01/22/18
01/22
12:45
01/22/18
12:45
Options
Qudian Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$44.82

0.34 (0.76%)

12:44
01/22/18
01/22
12:44
01/22/18
12:44
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel says made good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

INTC

Intel

$44.82

0.34 (0.76%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel recommends stopping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

BAC

Bank of America

$31.76

0.04 (0.13%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Periodicals
Bank of America eliminates remaining free-checking eBanking accounts, WSJ says »

Bank of America has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

MS

Morgan Stanley

$57.02

-0.44 (-0.77%)

12:38
01/22/18
01/22
12:38
01/22/18
12:38
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$45.78

2.43 (5.61%)

12:35
01/22/18
01/22
12:35
01/22/18
12:35
Options
Avis Budget put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

12:30
01/22/18
01/22
12:30
01/22/18
12:30
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

12:25
01/22/18
01/22
12:25
01/22/18
12:25
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

OMER

Omeros

$16.70

-0.02 (-0.12%)

12:24
01/22/18
01/22
12:24
01/22/18
12:24
Hot Stocks
Omeros off highs following cautious Twitter mention »

Shares of Omeros are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

, SPX

S&P 500

12:21
01/22/18
01/22
12:21
01/22/18
12:21
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Schumer says deal reached…

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$12.59

0.12 (0.96%)

12:20
01/22/18
01/22
12:20
01/22/18
12:20
Options
AMD attracts a bullish three-way spread before shares tick higher »

AMD attracts a bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

BG

Bunge

$80.40

2.84 (3.66%)

, ADM

Archer Daniels

$42.21

1.2505 (3.05%)

12:19
01/22/18
01/22
12:19
01/22/18
12:19
Recommendations
Bunge, Archer Daniels, Glencore analyst commentary  »

Credit Suisse says Archer…

BG

Bunge

$80.40

2.84 (3.66%)

ADM

Archer Daniels

$42.21

1.2505 (3.05%)

GLNCY

Glencore

$11.29

-0.02 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

$NSD

NASDAQ Market Internals

12:17
01/22/18
01/22
12:17
01/22/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/22/18
01/22
12:16
01/22/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$66.78

0.16 (0.24%)

12:15
01/22/18
01/22
12:15
01/22/18
12:15
Options
Kellogg put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

12:10
01/22/18
01/22
12:10
01/22/18
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

12:08
01/22/18
01/22
12:08
01/22/18
12:08
General news
On The Fly: Top stock stories at midday »

Stocks opened mixed, with…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

VR

Validus

$67.50

20.775 (44.47%)

SNY

Sanofi

$43.23

-1.37 (-3.07%)

CELG

Celgene

$102.65

0.93 (0.91%)

AIG

AIG

$61.03

-0.525 (-0.85%)

IDRA

Idera Pharmaceuticals

$2.55

0.145 (6.03%)

BCRX

BioCryst

$5.59

-0.09 (-1.58%)

SANM

Sanmina

$35.45

0.5 (1.43%)

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

FE

FirstEnergy

$33.23

3.83 (13.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 02

    Feb

  • 09

    Feb

  • 14

    Feb

  • 16

    Feb

  • 20

    Feb

  • 21

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

  • 30

    Jun

  • 30

    Jun

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Periodicals
Senators have enough votes to end government shutdown, NBC reports 

Reference Link

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, SNY

Sanofi

$43.22

-1.385 (-3.11%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Hot Stocks
Hemophilia makers jump after Sanofi acquires peer Bioverativ for huge premium »

Shares of drug companies…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

SNY

Sanofi

$43.22

-1.385 (-3.11%)

PFE

Pfizer

$36.88

-0.06 (-0.16%)

JNJ

Johnson & Johnson

$147.21

-0.15 (-0.10%)

ALNY

Alnylam

$124.83

0.84 (0.68%)

CBIO

Catalyst Biosciences

$19.49

0.86 (4.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 25

    Jan

  • 30

    Jan

  • 06

    Feb

  • 08

    Feb

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

IRIX

IRIDEX

$7.46

-0.11 (-1.45%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Hot Stocks
BlueLine Partners reports 8.5% passive stake in IRIDEX »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLN

Olin

$37.04

0.155 (0.42%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Options
Opening activity in Olin calls »

Opening activity in Olin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

BK

BNY Mellon

$57.21

0.6 (1.06%)

11:58
01/22/18
01/22
11:58
01/22/18
11:58
Hot Stocks
BNY Mellon to launch FX prime brokerage service »

BNY Mellon announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

, CELG

Celgene

$102.65

0.93 (0.91%)

11:54
01/22/18
01/22
11:54
01/22/18
11:54
Downgrade
Juno Therapeutics, Celgene rating change  »

Juno Therapeutics…

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

CELG

Celgene

$102.65

0.93 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

PM

Philip Morris

$109.21

0.29 (0.27%)

, XXII

22nd Century

$3.94

0.08 (2.07%)

11:52
01/22/18
01/22
11:52
01/22/18
11:52
Periodicals
FDA advisers to vote on clearance for Philip Morris iQOS device, Reuters says »

U.S. health advisers are…

PM

Philip Morris

$109.21

0.29 (0.27%)

XXII

22nd Century

$3.94

0.08 (2.07%)

BTI

British American Tobacco

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPZ

Williams Partners

$43.16

0.61 (1.43%)

11:50
01/22/18
01/22
11:50
01/22/18
11:50
Options
Williams Partners with notable call buying »

Williams Partners with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.